Biohope is awarded for its innovation by the European Investment Bank (EIB)

Published On: July 11th, 2024

At the ‘EIB AdVenture Debt Summit’, Biohope received one of the ‘Innovation Champion Awards’ from the European Investment Bank (EIB) for its development of innovative projects in the field of precision medicine.

Isabel Portero, CEO and founder of Biohope, received the award in Luxembourg. “It is a great satisfaction to receive this recognition among leading companies from all sectors; they are the future of Europe, a future in which we will also be a part,” she stated. “This encourages us to maintain our commitment to R&D in the field of biotechnology, to develop innovative products for the benefit of patients.”

Isabel Portero accepted the award during the ‘EIB AdVenture Debt and Advisory Summit’, at the European Convention Center in Luxembourg. The conference brought together CEOs and CFOs of companies from the EIB portfolio, as well as executives from venture capital and debt funds, leading advisors in the field of innovation and capital and growth, representatives of the European Commission, the EIB, and the media. The event focused on market trends, investment needs, and challenges for innovative companies. It is an opportunity to connect policymakers, business leaders, and experts.

The innovative personalized medicine projects for patients with autoimmune diseases and transplants received funding from the EIB through a ‘venture debt’ financing agreement, signed in 2023, between the Spanish biotechnology company and the EIB. This financing agreement, amounting to 15 million euros, is supported by the InvestEU program, which aims to mobilize over 372 billion euros in additional investment in the period 2021-2027.

The agreement is framed in the research, innovation, and digitalization action area of the InvestEU program, fields in which Biohope stands out at the European level.

The purpose of the financing agreed with Biohope is the internationalization of the company, along with its first product for kidney transplantation; and the development and validation of its pipeline of personalized and precision medicine products for chronic autoimmune diseases. The total project cost is estimated at 34 million euros.

In collaboration with the European Commission and the Member States, the European Investment Bank is a key growth capital financing provider in Europe, supporting highly innovative European companies in early stages during critical phases of their development.

If you want to read more about it in the Spanish news: